Genetic immunization, or DNA vaccination, is an innovative method of vaccine development that involves introducing genetic material into the body to stimulate an immune response. Unlike traditional vaccines, which contain weakened or inactivated pathogens, genetic vaccines deliver a piece of the pathogen’s DNA or RNA directly into the cells. The cells then produce the pathogen’s proteins, which the immune system recognizes as foreign, triggering an immune response. This technique offers several advantages, including the ability to quickly design vaccines against new and emerging pathogens. It also eliminates the need for growing pathogens in the lab, which can be time-consuming and difficult for some organisms. Genetic vaccines have been explored for a variety of diseases, including Zika virus, influenza, and cancer. This approach has also shown promise in veterinary medicine, with vaccines being developed for livestock and pets. The flexibility and speed of genetic immunization techniques position them as a powerful tool in the fight against infectious diseases.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States